Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cadence nets $49mm with private share offering

Executive Summary

Cadence Pharmaceuticals (drugs for the hospital market) netted $49mm through the sale of 9.24mm common shares priced at $5.34 each (a 6% discount) to selected investors. The company will use some of the funds for ongoing Phase III trials of Acetavance (acetaminophen) for acute pain.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies